Severe Combined Immunodeficiency (SCID)
Symptoms, Doctors, Treatments, Advances & More

Severe Combined Immunodeficiency (SCID) Overview

Save information for later
Sign Up

Learn About Severe Combined Immunodeficiency (SCID)

What is the definition of Severe Combined Immunodeficiency (SCID)?
Severe combined immunodeficiencies (SCID) are inherited immune system disorders characterized by abnormalities with responses of both T cells and B cells (specific types of white blood cells needed for immune system function). Common signs and symptoms include an increased susceptibility to infections including ear infections; pneumonia or bronchitis; oral thrush; and diarrhea. Due to recurrent infections, children with SCID do not grow and gain weight as expected (failure to thrive). SCID may be caused by genetic changes in any of several genes and can be inherited in an X-linked recessive (most commonly) or autosomal recessive manner. The most common type of SCID is called X-linked Severe combined immunodeficiency (XSCID). Another form of SCID is caused by a deficiency of the enzyme adenosine deaminase (ADA).
What are the alternative names for Severe Combined Immunodeficiency (SCID)?
  • Severe combined immunodeficiency
  • SCID
Who are the top Severe Combined Immunodeficiency (SCID) Local Doctors?
Jolan E. Walter
Elite in Severe Combined Immunodeficiency (SCID)
Dr. Jolan E. Walter
Pediatric Allergy and Immunology
Elite in Severe Combined Immunodeficiency (SCID)
Dr. Jolan E. Walter
Pediatric Allergy and Immunology

St Petersburg Outpatient Care Center - University Of South Florida - Allergy & Immunology

St Petersburg, FL 
727-828-6390
Languages Spoken:
English, Hungarian
See accepted insurances
Offers Telehealth

Jolan Walter is a Pediatric Allergy and Immunologist in St Petersburg, Florida. Dr. Walter is rated as an Elite provider by MediFind in the treatment of Severe Combined Immunodeficiency (SCID). Her top areas of expertise are Severe Combined Immunodeficiency (SCID), Primary Immunodeficiency (PID), Infantile Neutropenia, and Common Variable Immune Deficiency.

Andrew R. Gennery
Elite in Severe Combined Immunodeficiency (SCID)
Andrew R. Gennery
Elite in Severe Combined Immunodeficiency (SCID)
Andrew R. Gennery
Queen Victoria Road, 
Newcastle Upon Tyne, ENG, GB 

Andrew Gennery practices in Newcastle Upon Tyne, United Kingdom. Mr. Gennery is rated as an Elite expert by MediFind in the treatment of Severe Combined Immunodeficiency (SCID). His top areas of expertise are Primary Immunodeficiency (PID), Severe Combined Immunodeficiency (SCID), Chronic Granulomatous Disease, Bone Marrow Transplant, and Heart Transplant.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Severe Combined Immunodeficiency (SCID)
Dr. Christopher Dvorak
Hematology | Oncology
Elite in Severe Combined Immunodeficiency (SCID)
Dr. Christopher Dvorak
Hematology | Oncology

Office

550 16th St Fl 4, 
San Francisco, CA 
415-476-0554
Languages Spoken:
English
See accepted insurances

Christopher Dvorak is a Hematologist and an Oncologist in San Francisco, California. Dr. Dvorak is rated as an Elite provider by MediFind in the treatment of Severe Combined Immunodeficiency (SCID). His top areas of expertise are Severe Combined Immunodeficiency (SCID), Juvenile Myelomonocytic Leukemia (JMML), Hepatic Venoocclusive Disease with Immunodeficiency, Bone Marrow Transplant, and Splenectomy.

View All Doctors
What are the latest Severe Combined Immunodeficiency (SCID) Clinical Trials?
A Phase I/II Safety and Efficacy Study of Gene Transfer for Artemis-Deficient Severe Combined Immunodeficiency (ART-SCID) in Newly Diagnosed Patients Using a Self-Inactivating Lentiviral Vector (AProArt) to Transduce Autologous CD34 Hematopoietic Cells (AProArt-CD34)
A Phase I/II Safety and Efficacy Study of Gene Transfer for Artemis-Deficient Severe Combined Immunodeficiency (ART-SCID) in Newly Diagnosed Patients Using a Self-Inactivating Lentiviral Vector (AProArt) to Transduce Autologous CD34 Hematopoietic Cells (AProArt-CD34)
Who is this study for: Child to adult patients with Combined Immunodeficiency
Enrollment Status: Recruiting
Publish Date: February 12, 2026
Intervention Type: Device, Drug
Study Drugs: Busulfan, AProArt Lentiviral-Transduced Autologous Hematopoietic Stem Cell Infusion
Study Phase: Phase 1/Phase 2

Summary: This study aims to determine if a new method can be used to treat Artemis-deficient Severe Combined Immunodeficiency (ART-SCID), a severe form of primary immunodeficiency caused by mutations in the DCLRE1C gene. This method involves transferring a normal copy of the DCLRE1C gene into stem cells of an affected patient. Participants will receive an infusion of stem cells transduced with a self-inact...

Match to trials
Find the right clinical trials for you in under a minute
Get started
The Determination of Genetic Basis Of Immunodeficiency
The Determination of Genetic Basis Of Immunodeficiency
Enrollment Status: Recruiting
Publish Date: January 08, 2026

Summary: This study will examine the role of hereditary factors in different forms of severe combined immunodeficiency (SCID). Patients with immunodeficiencies may be eligible for this study. Candidates include: * Patients with diminished numbers of T cells or NK cells or both, or * Patients with normal T cell and NK cell numbers but diminished T cell, B cell, or NK cell function. Relatives of patients wil...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center